Main ongoing clinical trials of ADCs in endometrial and cervical cancer
| Target | ADC | Trial | Phase | Setting | Treatment | Primary endpoint |
|---|---|---|---|---|---|---|
| HER2 | Trastuzumab duocarmazine (SYD985) | NCT04205630 | II | HER2 pos metastatic endometrial cancer | Trastuzumab duocarmazine | ORR |
| T-DXd | NCT04482309 | II | HER2 pos tumors including ovarian, endometrial, and cervical cancer | T-DXd | ORR | |
| FRα | Mirvetuximab soravtansine | NCT03832361 | II | FRα pos persistent or recurrent endometrial cancer | Mirvetuximab soravtansine | ORR |
| NCT03835819 | II | FRα pos advanced or recurrent serous endometrial cancer | Mirvetuximab soravtansine + pembrolizumab | ORR/PFS | ||
| Trop2 | Sacituzumab govitecan | NCT04251416 | II | Trop2 pos persistent or recurrent endometrial cancer | Sacituzumab govitecan | ORR |
| TF | Tisotumab vedotin | InnovaTV 301(NCT04697628) | III | Previously treated recurrent or metastatic cervical cancer | Tisotumab vedotin vs. chemotherapy | OS |